G
G

GSK

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

British Business - Oct. 15

Oct 15 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - GlaxoSmithKline Plc GSK.L is embroiled in a row with activist investor Bluebell after it called for the replacement of the drugs group's chairman and chief execut
A
G
S

Financial Times - Oct 13

Oct 13 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - THG shares tumble after chief hits out at short sellers Link - GlaxoSmithKline activist calls for chair to quit Link - UK's recovery will lag behind other G7 nations, IMF forecasts Li
G

British Business - Oct. 13

Oct 13 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - A key investor presentation intended to soothe City jitters over THG Plc THG.L backfired spectacularly on Tuesday when it was followed by a barrage of sell orders
G

African Union to start talks with WHO on malaria vaccine rollout

By Maggie Fick NAIROBI, Oct 7 (Reuters) - Africa will start talks with the World Health Organization about getting the first approved malaria vaccine to the continent as soon as possible, the African Union's top health official said on Thursday, amid calls for funding for drugs beyond COVID-19. John Nkengasong spoke a day after the WHO said RTS,S -
G

African Union to start talks with WHO on malaria vaccine rollout on continent

By Maggie Fick NAIROBI, Oct 7 (Reuters) - Africa will start talks with the World Health Organization about getting the first approved malaria vaccine to the continent as soon as possible, the African Union's top health official said on Thursday, amid calls for funding for drugs beyond COVID-19. John Nkengasong spoke a day after the WHO said Link RT
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.